Sugi Predict

Sugi Predict / Targets / PSD

PSD

PH and SEC7 domain-containing protein 1 · A5PKW4 · PSD on Sugi Atlas →

4,813 patent compounds predicted against PSD, 2,234 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3766356 SCHEMBL3766356 0.58 13/20
SCHEMBL3751904 SCHEMBL3751904 0.50 9/20
SCHEMBL1278782 SCHEMBL1278782 0.43 7/20
SCHEMBL1924686 SCHEMBL1924686 0.50 6/20
SCHEMBL3562903 SCHEMBL3562903 0.48 6/20
SCHEMBL5065616 SCHEMBL5065616 0.45 5/20
SCHEMBL1125105 SCHEMBL1125105 0.42 5/20
SCHEMBL3559155 SCHEMBL3559155 0.41 5/20
SCHEMBL4237052 SCHEMBL4237052 0.35 5/20
SCHEMBL4779395 SCHEMBL4779395 0.52 4/20
SCHEMBL2649481 SCHEMBL2649481 0.50 4/20
SCHEMBL3562751 SCHEMBL3562751 0.46 4/20
SCHEMBL3565117 SCHEMBL3565117 0.45 4/20
SCHEMBL3559622 SCHEMBL3559622 0.44 4/20
SCHEMBL6466251 SCHEMBL6466251 0.43 4/20
SCHEMBL4659264 SCHEMBL4659264 0.48 3/20
SCHEMBL6031821 SCHEMBL6031821 0.43 3/20
SCHEMBL3568765 SCHEMBL3568765 0.41 3/20
SCHEMBL1279352 SCHEMBL1279352 0.41 3/20
SCHEMBL3563165 SCHEMBL3563165 0.39 3/20

Clinical trials — most relevant to PSD by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ketamine Treatment Effects on Synaptic Plasticity in Depression PHASE4COMPLETED
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) PHASE4COMPLETED
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) PHASE2/PHASE3RECRUITING
Minocycline for the Treatment of Early-Phase Schizophrenia PHASE3COMPLETED
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy EARLY_PHASE1ACTIVE_NOT_RECRUITING
Observational Study on Determinants of Dementia After Stroke nanACTIVE_NOT_RECRUITING
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy nanUNKNOWN
Protein Synthesis in the Brain of Patients With Fragile X Syndrome nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients nanNOT_YET_RECRUITING
Study of the Genetic Factors Involved in Autism and Related Disorders nanRECRUITING
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease nanNOT_YET_RECRUITING
Combined Aerobic Exercise and Cognitive Training in Seniors at Increased Risk for Alzheimer's Disease nanNOT_YET_RECRUITING
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression nanRECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Research on the Early and Prognosis Diagnosis of Vascular Dementia nanRECRUITING
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment nanUNKNOWN
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSD binder may also engage these)

ProteinNameSimilarity
Q5DTT2 — 1.000 Q5DTT2 →
A2AEV7 — 0.997 A2AEV7 →
F1MUS9 — 0.996 F1MUS9 →
Q3KP66 — 0.995 Q3KP66 →
Q80UW3 — 0.994 Q80UW3 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.993 landscape →
E9Q9W7 — 0.992 E9Q9W7 →
Q9BQI7 — 0.992 Q9BQI7 →
Q9H5P4 — 0.991 Q9H5P4 →
Q9H329 — 0.991 Q9H329 →
Q60700 — 0.991 Q60700 →
Q9ESQ7 — 0.991 Q9ESQ7 →
C9JTQ0 — 0.991 C9JTQ0 →
Q6DN90 — 0.991 Q6DN90 →
Q08274 — 0.991 Q08274 →
Q9Z0Y7 — 0.991 Q9Z0Y7 →
O14512 — 0.990 O14512 →
Q0X0C4 — 0.990 Q0X0C4 →
Q9P1Y5 — 0.990 Q9P1Y5 →
Q8WUF5 — 0.990 Q8WUF5 →
P57100 — 0.990 P57100 →
Q8JZP9 — 0.990 Q8JZP9 →
Q9Y4B5 — 0.990 Q9Y4B5 →
O94992 — 0.990 O94992 →
A2ARS0 — 0.990 A2ARS0 →
Q6R6L0 — 0.989 Q6R6L0 →
Q8BGT6 — 0.989 Q8BGT6 →
Q6P1I6 — 0.989 Q6P1I6 →
Q91XC0 — 0.989 Q91XC0 →
P97838 — 0.989 P97838 →